HER1 Vaccine: An autologous EGFR vaccine candidate to treat epithelial tumors



Título del documento: HER1 Vaccine: An autologous EGFR vaccine candidate to treat epithelial tumors
Revista: Biotecnología aplicada
Base de datos: PERIÓDICA
Número de sistema: 000349776
ISSN: 0864-4551
Autores: 1
1
1
1
1
1
Instituciones: 1Centro de Inmunología Molecular, La Habana. Cuba
Año:
Volumen: 26
Número: 4
Paginación: 342-344
País: Cuba
Idioma: Inglés
Tipo de documento: Artículo
Enfoque: Experimental, aplicado
Resumen en inglés The Epidermal Growth Factor Receptor (EGFR) plays an essential role in regulating neoplastic processes. EGFR over-expression in many human epithelial tumors has been correlated with disease progression and bad prognosis. Passive EGFR-directed immunotherapy has been introduced in medical oncology practice, but no active specific approaches have been used. We designed a vaccine candidate based on the extracellular domain (ECD) of human EGFR (HER1), and the homologous vaccine for mice based on murine EGFR. This vaccine candidate uses the Very Small-Sized Proteoliposomes from Neisseria meningitidis (VSSP) and Montanide ISA 51-VG as adjuvants. The autologous vaccine circumvents the tolerance to self EGFR by inducing a specific immune response with an anti-metastatic effect on EGFR+ tumors. The vaccine candidate based on HER1-ECD induced anti-EGFR polyclonal antibodies (PAb) that bind EGFR+ human tumor cell lines from different tissues. These anti-EGFR PAb abrogate ligand-dependent EGFR phosphorylation, provoking the inhibition of tumor cell growth and apoptosis. Preclinical results further encouraged the evaluation of the HER1 vaccine candidate in phase I clinical trials
Disciplinas: Medicina
Palabras clave: Oncología,
Inmunología,
Tumores epiteliales,
Vacunas,
Factor de crecimiento epidérmico
Keyword: Medicine,
Oncology,
Immunology,
Epithelial tumors,
Vaccines,
Epidermal growth factor
Texto completo: Texto completo (Ver PDF)